GlassScriptPhysician profile
Lucy W Ibrahim
NPI 1184610107
$362.89
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Addiction Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $85.59 · 2022: $22.35.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $96.37 | 2019 | |
| Allergan, INC. | $65.05 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $48.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.22 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $35.85 | 2020 | |
| Abbvie INC. | $22.35 | 2022 | |
| Shire North American Group INC | $21.95 | 2019 | |
| Vanda Pharmaceuticals INC. | $21.88 | 2019 | |
| Neos Therapeutics, LP | $14.08 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$18,115,049.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.